To identify potential regulatory impact of the PI3K/AKT/mTOR on eIF expression upon chemosensitivity testing, members of this signalling were investigated at the protein level in the treated GBM PDX (Figure S4). This evidence concerns the gene AKT1 and glioblastoma.